Loading
The UK-led prevention trial that showed five years of tamoxifen keeps preventing breast cancer for at least twenty years, and the reason NICE tells the NHS to offer it to premenopausal women at high familial risk.
IBIS-I randomised 7,154 women at increased risk of breast cancer to tamoxifen or placebo for five years. At a median 16 years of follow-up, breast cancer (invasive plus ductal carcinoma in situ) occurred in 251 women in the tamoxifen arm and 350 in the placebo arm, a hazard ratio of 0.71, with the reduction as large after ten years as during the first ten; the effect was confined to oestrogen-receptor-positive disease and there was no difference in breast cancer mortality. Endometrial cancer and thromboembolism were increased mainly while the drug was being taken. With the American NSABP P-1 trial it is the evidence behind NICE CG164 recommendation 1.7.21, which tells the NHS to offer tamoxifen for five years to premenopausal women at high risk.
Shares Jack Cuzick, Tamoxifen, Breast cancer (all types) and the tags uk, breast, prevention.
Shares Breast cancer (all types) and the tags uk, breast.
Shares Breast cancer (all types) and the tags uk, breast.
Shares Breast cancer (all types) and the tags uk, breast.
Shares Breast cancer (all types) and the tags uk, breast.
Shares Breast cancer (all types) and the tags breast, prevention.
Shares Tamoxifen, Breast cancer (all types) and the tag breast.
Shares Tamoxifen, Breast cancer (all types).